A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this study is to determine if the study drug, patritumab deruxtecan (HER3-DXd), can be measured in brain tumor tissue after recieving one dose of patritumab deruxtecan before surgery.
Epistemonikos ID: cf1268ada8e203c6a9e830cafcc2ed2fca9b2f24
First added on: May 14, 2024